JP2005528337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528337A5 JP2005528337A5 JP2003558463A JP2003558463A JP2005528337A5 JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5 JP 2003558463 A JP2003558463 A JP 2003558463A JP 2003558463 A JP2003558463 A JP 2003558463A JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- gly
- ser
- glp
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 41
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 41
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 32
- 238000012217 deletion Methods 0.000 claims 28
- 230000037430 deletion Effects 0.000 claims 28
- 150000001413 amino acids Chemical group 0.000 claims 16
- 229960002885 histidine Drugs 0.000 claims 16
- 229940024606 amino acid Drugs 0.000 claims 12
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 claims 4
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims 4
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 4
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 229930195721 D-histidine Natural products 0.000 claims 4
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 4
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 4
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 4
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 4
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000002437 D-histidyl group Chemical group N[C@@H](C(=O)*)CC=1N=CNC1 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34647402P | 2002-01-08 | 2002-01-08 | |
| US40509702P | 2002-08-21 | 2002-08-21 | |
| PCT/US2003/000001 WO2003058203A2 (en) | 2002-01-08 | 2003-01-03 | Extended glucagon-like peptide-1 analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005528337A JP2005528337A (ja) | 2005-09-22 |
| JP2005528337A5 true JP2005528337A5 (enExample) | 2006-02-02 |
| JP4282485B2 JP4282485B2 (ja) | 2009-06-24 |
Family
ID=26994870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003558463A Expired - Fee Related JP4282485B2 (ja) | 2002-01-08 | 2003-01-03 | 伸長グルカゴン様ペプチド−1アナログ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7482321B2 (enExample) |
| EP (1) | EP1585959A4 (enExample) |
| JP (1) | JP4282485B2 (enExample) |
| AR (1) | AR038102A1 (enExample) |
| AU (1) | AU2003200839B2 (enExample) |
| BR (1) | BR0306706A (enExample) |
| CA (1) | CA2468700A1 (enExample) |
| MX (1) | MXPA04006679A (enExample) |
| PE (1) | PE20030820A1 (enExample) |
| TW (1) | TW200306202A (enExample) |
| WO (1) | WO2003058203A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7557183B2 (en) | 2003-03-19 | 2009-07-07 | Eli Lilly And Company | Polyethylene glycol linked GLP-1 compounds |
| WO2005056036A2 (en) | 2003-12-09 | 2005-06-23 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
| EP1709071A4 (en) | 2004-01-08 | 2007-05-30 | Theratechnologies Inc | GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE |
| US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
| WO2006023367A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| US8097586B2 (en) | 2005-01-14 | 2012-01-17 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Modified exedins and uses thereof |
| ES2484796T3 (es) | 2005-03-18 | 2014-08-12 | Novo Nordisk A/S | Compuestos de GLP-1 extendidos |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2007017892A2 (en) * | 2005-05-05 | 2007-02-15 | Cadila Healthcare Limited | Novel compounds as glp-i agonists |
| SI1881850T1 (sl) * | 2005-05-13 | 2011-01-31 | Lilly Co Eli | Glp-1 pegilirane spojine |
| WO2007021498A1 (en) * | 2005-08-11 | 2007-02-22 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| RS51319B (sr) * | 2005-09-22 | 2010-12-31 | Biocompatibles Uk Limited | GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE |
| KR101057284B1 (ko) | 2005-10-26 | 2011-08-16 | 일라이 릴리 앤드 캄파니 | 선택적 vpac2 수용체 펩티드 작동제 |
| PL1965823T3 (pl) * | 2005-11-04 | 2017-08-31 | Glaxosmithkline Llc | Sposoby podawania środków hipoglikemicznych |
| CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
| JP2009528376A (ja) * | 2006-02-28 | 2009-08-06 | イーライ リリー アンド カンパニー | 選択的vpac2受容体ペプチドアゴニスト |
| WO2007113205A1 (en) * | 2006-04-03 | 2007-10-11 | Novo Nordisk A/S | Glp-1 peptide agonists |
| EP2007804B1 (en) | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1 compounds |
| EP1854455B1 (en) | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | Spherical microcapsules comprising GLP-1 peptides, their production and use |
| JO2945B1 (en) | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods of giving prolonged hypoglycemic agents |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
| EP1975176A1 (en) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Novel glp-1 fusion peptides, their production and use |
| US20110034373A1 (en) * | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| TWI541023B (zh) * | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| DK2344519T3 (en) | 2008-11-07 | 2017-01-23 | Massachusetts Gen Hospital | C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1) |
| HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
| EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트 |
| EP2566502A4 (en) | 2010-05-04 | 2013-10-09 | Glaxosmithkline Llc | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION |
| RU2012153753A (ru) | 2010-05-13 | 2014-06-20 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов |
| ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
| US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| US9040481B2 (en) | 2010-11-02 | 2015-05-26 | The General Hospital Corporation | Methods for treating steatotic disease |
| CN105748402B (zh) | 2010-11-24 | 2022-06-03 | 杜雷科特公司 | 生物可降解的药物递送组合物 |
| NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| JP6184404B2 (ja) | 2011-06-22 | 2017-08-23 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン/glp−1レセプターコアゴニスト |
| EP2729157B1 (en) * | 2011-07-06 | 2019-01-16 | The General Hospital Corporation | A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| BR112014007124A2 (pt) | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| TW201334791A (zh) | 2011-11-23 | 2013-09-01 | 杜瑞克公司 | 輻射滅菌之可生物降解之藥物遞送組合物 |
| ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| AU2014283221A1 (en) * | 2013-06-20 | 2015-12-03 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー/エス | Glp−1誘導体及びその使用 |
| EP3233898A1 (en) | 2014-12-17 | 2017-10-25 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| SMT202200352T1 (it) | 2018-04-05 | 2022-09-14 | Sun Pharmaceutical Ind Ltd | Analoghi del glp-1 innovativi |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) * | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| EP1060191B1 (en) * | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| SI1724284T1 (sl) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| EP1411968B1 (en) * | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| WO2003020201A2 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| EP1448222A4 (en) * | 2001-10-19 | 2006-05-17 | Lilly Co Eli | BIPHASIC MIXTURES OF GLP-1 AND INSULIN |
-
2003
- 2003-01-03 AR ARP030100014A patent/AR038102A1/es unknown
- 2003-01-03 MX MXPA04006679A patent/MXPA04006679A/es unknown
- 2003-01-03 EP EP03700026A patent/EP1585959A4/en not_active Withdrawn
- 2003-01-03 CA CA002468700A patent/CA2468700A1/en not_active Abandoned
- 2003-01-03 AU AU2003200839A patent/AU2003200839B2/en not_active Ceased
- 2003-01-03 WO PCT/US2003/000001 patent/WO2003058203A2/en not_active Ceased
- 2003-01-03 JP JP2003558463A patent/JP4282485B2/ja not_active Expired - Fee Related
- 2003-01-03 US US10/499,111 patent/US7482321B2/en not_active Expired - Fee Related
- 2003-01-03 TW TW092100093A patent/TW200306202A/zh unknown
- 2003-01-03 BR BRPI0306706-8A patent/BR0306706A/pt not_active IP Right Cessation
- 2003-01-06 PE PE2003000021A patent/PE20030820A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10961287B2 (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2008533105A5 (enExample) | ||
| EP3398961B1 (en) | Triple activator activating glucagon, glp-1 and gip receptor | |
| JP2014529629A5 (enExample) | ||
| CN101993485B (zh) | 促胰岛素分泌肽类似物同源二聚体及其用途 | |
| RU2006120079A (ru) | Производные глюкагоноподобного пептида-1 (glp-1) | |
| JP2003505347A5 (enExample) | ||
| JP2001011095A5 (enExample) | ||
| RU2007119990A (ru) | Слитые конструкции лекарственного средства и конъюгаты | |
| JP4227894B2 (ja) | グルカゴン様ペプチド1アナログ | |
| EP2729481B1 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2013517307A5 (enExample) | ||
| JP2013543853A5 (enExample) | ||
| PE20231842A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| TW201010729A (en) | GIP-based mixed agonists for treatment of metabolic disorders and obesity | |
| JP2002538081A (ja) | Glp−1の類似体 | |
| JP2005528337A (ja) | 伸長グルカゴン様ペプチド−1アナログ | |
| JP2007519642A5 (enExample) | ||
| TW200848423A (en) | Glucagon/GLP-1 receptor co-agonists | |
| JP2014501712A5 (enExample) | ||
| AU2003200839A2 (en) | Extended glucagon-like peptide-1 analogs | |
| JP2012529297A5 (enExample) | ||
| JP2005519059A5 (enExample) | ||
| RU2005115477A (ru) | Нейтрализующие антитела против gdf-8 и их применение | |
| JP2004501162A5 (enExample) |